Skip to main content
We Study Billionaires

TIP832: Fairfax Financial (FFO.TO): The Berkshire Of The North w/ Kyle Grieve & Shawn O'Malley

66 min episode · 3 min read
·

Episode

66 min

Read time

3 min

Topics

Career Growth, Investing, Fundraising & VC

AI-Generated Summary

Key Takeaways

  • Float as free leverage: Fairfax grew its insurance float from $13M in 1985 to $40.8B today by acquiring underperforming insurers and deploying float capital at 7.7% long-term returns versus the industry average of ~4%. When combined with a sub-100% combined ratio (averaging ~97% since 2006), the company effectively gets paid to hold and invest other people's money — a structural advantage most insurers never achieve simultaneously.
  • Post-GFC hedging mistake: Fairfax netted $4.6B from CDS bets during the 2008 crisis — four times Michael Burry's gain — but then spent 2010–2016 shorting the S&P 500 and Russell 2000, wiping out nearly all operating income and limiting book value growth to 2% annually. Watsa publicly admitted the error and permanently abandoned shorting. Investors should recognize that crisis-era scars systematically distort future risk assessments, even for elite capital allocators.
  • Tactical buyback execution: During COVID-19, Fairfax purchased total return swaps on its own stock after shares dropped ~50%, ultimately generating ~$2B in cash proceeds used for further share repurchases. Share count declined from 28M to 23M since 2018, with buybacks executed at prices as low as $473–$500 versus today's ~$2,340. Timing buybacks at maximum pessimism, not all-time highs, is the key differentiator between value-destructive and value-creative capital return programs.
  • Non-dilutive options structure: Fairfax grants equity awards using shares already purchased on the open market rather than newly issued shares, making compensation entirely non-dilutive — a structure described as exceptionally rare. Vesting runs 50% at five years and 50% at ten years, with expiration dates extending past 2040. This forces boards to treat compensation as a real cash expense, naturally constraining package sizes and aligning executive time horizons with long-term shareholder value creation.
  • Insurance valuation framework: Evaluate insurance holding companies using return on equity rather than ROIC, then apply a price-to-book multiple to terminal book value. At Fairfax's stated 15% ROE target (below its five-year average of ~21%), applying a 1.3x book multiple produces a 2030 terminal value of ~CAD $4,600 including dividends, implying ~14.7% annualized returns. Bear case at 11% ROE with 1.0x book still yields ~5.3% annually, demonstrating meaningful downside protection.

What It Covers

Kyle Grieve and Shawn O'Malley analyze Fairfax Financial (FFH.TO), a Canadian insurance holding company led by Prem Watsa that has compounded book value at 18% annually since 1985. The episode covers Fairfax's business model, GFC bet, capital allocation strategies, competitive advantages, management structure, valuation, and comparison to Berkshire Hathaway.

Key Questions Answered

  • Float as free leverage: Fairfax grew its insurance float from $13M in 1985 to $40.8B today by acquiring underperforming insurers and deploying float capital at 7.7% long-term returns versus the industry average of ~4%. When combined with a sub-100% combined ratio (averaging ~97% since 2006), the company effectively gets paid to hold and invest other people's money — a structural advantage most insurers never achieve simultaneously.
  • Post-GFC hedging mistake: Fairfax netted $4.6B from CDS bets during the 2008 crisis — four times Michael Burry's gain — but then spent 2010–2016 shorting the S&P 500 and Russell 2000, wiping out nearly all operating income and limiting book value growth to 2% annually. Watsa publicly admitted the error and permanently abandoned shorting. Investors should recognize that crisis-era scars systematically distort future risk assessments, even for elite capital allocators.
  • Tactical buyback execution: During COVID-19, Fairfax purchased total return swaps on its own stock after shares dropped ~50%, ultimately generating ~$2B in cash proceeds used for further share repurchases. Share count declined from 28M to 23M since 2018, with buybacks executed at prices as low as $473–$500 versus today's ~$2,340. Timing buybacks at maximum pessimism, not all-time highs, is the key differentiator between value-destructive and value-creative capital return programs.
  • Non-dilutive options structure: Fairfax grants equity awards using shares already purchased on the open market rather than newly issued shares, making compensation entirely non-dilutive — a structure described as exceptionally rare. Vesting runs 50% at five years and 50% at ten years, with expiration dates extending past 2040. This forces boards to treat compensation as a real cash expense, naturally constraining package sizes and aligning executive time horizons with long-term shareholder value creation.
  • Insurance valuation framework: Evaluate insurance holding companies using return on equity rather than ROIC, then apply a price-to-book multiple to terminal book value. At Fairfax's stated 15% ROE target (below its five-year average of ~21%), applying a 1.3x book multiple produces a 2030 terminal value of ~CAD $4,600 including dividends, implying ~14.7% annualized returns. Bear case at 11% ROE with 1.0x book still yields ~5.3% annually, demonstrating meaningful downside protection.
  • Decentralization as retention tool: Fairfax maintains presidents at subsidiary insurance companies for multiple decades by acquiring well-run businesses and leaving management structures intact. Internal promotion is the default, not the exception. This matters in insurance specifically because underwriting quality only reveals itself across multiple cycles — firing managers mid-cycle before reserve deficiencies or redundancies surface destroys institutional knowledge and resets the underwriting improvement timeline by years.

Notable Moment

Fairfax sold a 10% stake in its Odyssey reinsurance subsidiary at 1.7x book value — a premium multiple — then used those proceeds to repurchase Fairfax shares trading at just 0.9x book. The maneuver simultaneously monetized an overvalued asset and bought an undervalued one, concentrating shareholder ownership without issuing new capital.

Know someone who'd find this useful?

You just read a 3-minute summary of a 63-minute episode.

Get We Study Billionaires summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

More from We Study Billionaires

We summarize every new episode. Want them in your inbox?

Similar Episodes

Related episodes from other podcasts

Explore Related Topics

This podcast is featured in Best Investing Podcasts (2026) — ranked and reviewed with AI summaries.

Read this week's Investing & Markets Podcast Insights — cross-podcast analysis updated weekly.

You're clearly into We Study Billionaires.

Every Monday, we deliver AI summaries of the latest episodes from We Study Billionaires and 192+ other podcasts. Free for one show.

Start My Monday Digest

No credit card · Unsubscribe anytime